分析顺铂联合培美曲塞治疗晚期非鳞状非小细胞肺癌的临床有效性

To Analyze the Clinical Efficacy of Cisplatin Combined with Pemetrexed in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

目的评估顺铂与培美曲塞联合疗法对晚期非鳞状非小细胞肺癌患者的疗效。方法非随机选取2022年1月—2023年12月黔西市人民医院肿瘤科收治的60例晚期非鳞状非小细胞肺癌患者为研究对象,根据治疗方式不同分为两组,每组30例,分别实施培美曲塞单药治疗(培美曲塞组)和培美曲塞加顺铂联合治疗(联合顺铂组)。对比两组治疗效果,治疗前和一个化疗周期后的血清肿瘤标记物[神经元特异性烯醇酶(neuronspecific enolase,NSE)、细胞角蛋白19片段抗原21-1(cytoplasmic keratin 19 fragment antigen 21-1,CYFRA21-1)、癌胚抗原(carcinoembryonic antigen,CEA)],以及生活质量评分及不良反应发生情况。结果联合顺铂组总有效率为66.67%(20/30)高于培美曲塞组26.67%(8/30),差异有统计学意义(χ^(2)=10.111,P<0.05);化疗1个周期后,两组血清NSE、CYFRA21-1、CEA水平低于化疗前,且联合顺铂组低于培美曲塞组,差异有统计学意义(P均<0.05);化疗后联合顺铂组生活质量指标数值优于培美曲塞组,差异有统计学意义(P均<0.05);联合顺铂组的不良反应发生率低于培美曲塞组,差异有统计学意义(P<0.05)。结论对于晚期非鳞状非小细胞肺癌,顺铂联合培美曲塞的治疗方案能有效提升治疗有效率,降低血清肿瘤标记物水平,维护患者的生活质量,同时表现出较好的安全性。

Objective To evaluate the efficacy of combination therapy of cisplatin and pemetrexed in patients with advanced non-squamous non-small cell lung cancer.Methods Sixty patients with advanced non-squamous non-small cell lung cancer admitted to the Oncology Department of Qianxi People's Hospital from January 2022 to December 2023 were non-randomly selected as the study subjects,and divided into two groups according to different treatment methods,with 30 patients in each group,respectively receiving pemetrexed monotherapy(pemetrexed group)and pemetrexed plus cisplatin combined therapy(combined cisplatin group).Compared the treatment effect between the two groups,Serum tumor markers[neuronspecific enolase(NSE),cytoplasmic keratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA)],And the quality of life score and the occurrence of adverse reactions.Results The total effective rate of the combined cisplatin group was 66.67%(20/30)higher than 26.67%(8/30)of pemetrexed group,and the difference was statistically significant(χ^(2)=10.111,P<0.05).After 1 cycle of chemotherapy,the serum levels of NSE,Cyfra21-1 and CEA in 2 groups were lower than before chemotherapy,and the combined cisplatin group was lower than pemetrexed group,the difference were statistically significant(all P<0.05).After chemotherapy combined with cisplatin group was better than pemetrexed group,the differences were statistically significant(all P<0.05).The incidence of adverse reactions in combination with cisplatin group was lower than that in pemetrexed group,and the difference was statistically significant(P<0.05).Conclusion For advanced non-squamous non-small cell lung cancer,the combination of cisplatin and pemetrexed can effectively improve the treatment response rate,reduce the level of serum tumor markers,maintain the quality of life of patients,and show a good safety.